These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 26243393)

  • 1. Early evaluation of targeted therapy effectiveness in non-small cell lung cancer by dynamic contrast-enhanced CT.
    Qiao PG; Zhang HT; Zhou J; Li M; Ma JL; Tian N; Xing XD; Li GJ
    Clin Transl Oncol; 2016 Jan; 18(1):47-57. PubMed ID: 26243393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility of quantitative parameters of dynamically enhanced patterns of spiral computed tomography scanning integrated into tumour progression before targeted treatment of non-small cell lung cancer.
    Qiao PG; Huang Q; Zhou J; Wang XC; Li M; Ma JL; Tian N; Li GJ
    J Med Imaging Radiat Oncol; 2015 Apr; 59(2):216-20. PubMed ID: 25597329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (99m)Tc-3PRGD 2 SPECT/CT predicts the outcome of advanced nonsquamous non-small cell lung cancer receiving chemoradiotherapy plus bevacizumab.
    Ma Q; Min K; Wang T; Chen B; Wen Q; Wang F; Ji T; Gao S
    Ann Nucl Med; 2015 Jul; 29(6):519-27. PubMed ID: 25911312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecularly targeted therapy using bevacizumab for non-small cell lung cancer: a pilot study for the new CT response criteria.
    Lee HY; Lee KS; Hwang HS; Lee JW; Ahn MJ; Park K; Kim TS; Yi CA; Chung MJ
    Korean J Radiol; 2010; 11(6):618-26. PubMed ID: 21076587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Non-small cell lung cancer evaluated by first pass dynamic contrast-enhanced 16-slice spiral CT: correlation of tumor vascularity with pathological characteristics].
    Sun CJ; Yang ZG; Zhou XP; Zhou QH; Sun JT; Zhang SF; Li J; Yu JM; Zhang L
    Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):429-33. PubMed ID: 17974276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results.
    Frampas E; Lassau N; Zappa M; Vullierme MP; Koscielny S; Vilgrain V
    Eur J Radiol; 2013 May; 82(5):e205-11. PubMed ID: 23273822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
    de Jong EE; van Elmpt W; Leijenaar RT; Hoekstra OS; Groen HJ; Smit EF; Boellaard R; van der Noort V; Troost EG; Lambin P; Dingemans AC
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):8-16. PubMed ID: 27600280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Operable non-small cell lung cancer: correlation of volumetric helical dynamic contrast-enhanced CT parameters with immunohistochemical markers of tumor hypoxia.
    Mandeville HC; Ng QS; Daley FM; Barber PR; Pierce G; Finch J; Burke M; Bell A; Townsend ER; Kozarski R; Vojnovic B; Hoskin PJ; Goh V
    Radiology; 2012 Aug; 264(2):581-9. PubMed ID: 22700554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib.
    Tiseo M; Ippolito M; Scarlattei M; Spadaro P; Cosentino S; Latteri F; Ruffini L; Bartolotti M; Bortesi B; Fumarola C; Caffarra C; Cavazzoni A; Alfieri RR; Petronini PG; Bordonaro R; Bruzzi P; Ardizzoni A; Soto Parra HJ
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):299-307. PubMed ID: 24258456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of whole-tumor dual-input perfusion CT in predicting the effect of multiarterial infusion chemotherapy on advanced non-small cell lung cancer.
    Li XS; Fan HX; Fang H; Huang H; Song YL; Zhou CW
    AJR Am J Roentgenol; 2014 Nov; 203(5):W497-505. PubMed ID: 25341164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor response in patients with advanced non-small cell lung cancer: perfusion CT evaluation of chemotherapy and radiation therapy.
    Wang J; Wu N; Cham MD; Song Y
    AJR Am J Roentgenol; 2009 Oct; 193(4):1090-6. PubMed ID: 19770333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DCE-CT parameters as new functional imaging biomarkers at baseline and during immune checkpoint inhibitor therapy in patients with lung cancer - a feasibility study.
    Andersen MB; Drljevic-Nielsen A; Ehlers JH; Thorup KS; Baandrup AO; Palne M; Rasmussen F
    Cancer Imaging; 2024 Aug; 24(1):105. PubMed ID: 39135095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?
    Lind JS; Meijerink MR; Dingemans AM; van Kuijk C; Ollers MC; de Ruysscher D; Postmus PE; Smit EF
    Eur Radiol; 2010 Dec; 20(12):2890-8. PubMed ID: 20625738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging Tumor Response and Tumoral Heterogeneity in Non-Small Cell Lung Cancer Treated With Antiangiogenic Therapy: Comparison of the Prognostic Ability of RECIST 1.1, an Alternate Method (Crabb), and Image Heterogeneity Analysis.
    Yip C; Tacelli N; Remy-Jardin M; Scherpereel A; Cortot A; Lafitte JJ; Wallyn F; Remy J; Bassett P; Siddique M; Cook GJ; Landau DB; Goh V
    J Thorac Imaging; 2015 Sep; 30(5):300-7. PubMed ID: 26164165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of ¹⁸F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva); objective and symptomatic responses at 6 and 12 weeks.
    O'Brien ME; Myerson JS; Coward JI; Puglisi M; Trani L; Wotherspoon A; Sharma B; Cook G; Ashley S; Gunapala R; Chua S; Popat S
    Eur J Cancer; 2012 Jan; 48(1):68-74. PubMed ID: 22119198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenesis in non-small cell lung cancer: imaging with perfusion computed tomography.
    Ng QS; Goh V
    J Thorac Imaging; 2010 May; 25(2):142-50. PubMed ID: 20463533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Application of perfusion CT scan in assessing the treatment and predicting prognosis for lung cancer before and after chemotherapy/radiotherapy].
    Wang JW; Wu N; Song Y
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):54-7. PubMed ID: 19538871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use.
    Weber WA; Petersen V; Schmidt B; Tyndale-Hines L; Link T; Peschel C; Schwaiger M
    J Clin Oncol; 2003 Jul; 21(14):2651-7. PubMed ID: 12860940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of dynamic contrast enhanced computed tomography in patients with non-small-cell lung cancer scheduled for radiation therapy.
    Lazanyi KS; Abramyuk A; Wolf G; Tokalov S; Zöphel K; Appold S; Herrmann T; Baumann M; Abolmaali N
    Lung Cancer; 2010 Dec; 70(3):280-5. PubMed ID: 20371133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.